This article summarizes the outcomes from a pilot online curriculum on off-label prescribing, appraising pharmaceutical information, and talking with patients about advertised medications.
Reliable identification of the physician–patient relationship is necessary for accurate evaluation. Standardization of evidence-based attribution methods is essential to improve the value of healthcare.
Health plans have made substantial progress in the collection of language data and many are offering options for language services.
Meta-analyses of percutaneous coronary interventions in stable coronary artery disease are updated to include 2 recent large randomized controlled trials.
One-year persistence among new users of statins in Finland improved from 1995 to 1998, after which no substantial changes were observed up to 2004.
Targeting glucose control and managing cardiovascular (CV) risk factors may prevent future CV events, and have positive downstream impact by reducing costs to healthcare stakeholders.
Methods for better identifying malignant versus benign disease before nephrectomy could provide significant benefits to patients and payers.
Shifting from claims to integrated electronic health records to calculate quality metrics will improve reported quality attributable to data capture changes, not true quality improvements.
It is unclear which barriers cause the greatest threats to the successful implementation of an electronic health record (EHR). This paper prioritizes the potential threats to EHR adoption using a novel analytic strategy: item response theory.
Innovations are powering the evolution of patient-centered care, and health plans are at the center of this innovation story.
Algorithms based on managed care pharmacy data can efficiently identify persons at risk for undiagnosed chronic obstructive pulmonary disease.
This feasibility study of expanded emergency department screening identified a high prevalence of behavioral health conditions. Screening was successfully integrated into emergency visit idle times.
The success of recommendations to improve screening often rests on the availability of efficacious therapies, coverage policies, and other factors that enable and justify screening.
The annual price of monoclonal antibody therapies used in oncology and hematology is about $100,000 higher than those used in other disease states.